Kiniksa (KNSA) Q4 2025 earnings review
Blockbuster Trajectory: Profitability Achieved as ARCALYST Sales Surge
Kiniksa delivered a flawless FY25, transforming from a clinical-stage cash-burner into a highly profitable commercial engine. Q4 ARCALYST net product revenue skyrocketed 65% YoY to $202.1 million, capping a year that saw net income reverse from a $43.2 million loss in FY24 to a $59.0 million profit. The company’s execution is driving a paradigm shift in recurrent pericarditis treatment, heavily penetrating the multiple-recurrence market. FY26 guidance sets a massive $910 million midpoint target, signaling absolute confidence that the growth engine remains fully fueled, though percentage growth will naturally decelerate.
🐂 Bull Case
ARCALYST sales have grown sequentially for every quarter in 2025, reaching $677.6M for the year. With only 18% penetration into the 14,000-patient core target market, the runway is incredibly long.
With an annual operating cash flow that added $170M to the balance sheet (now at $414M, zero debt), Kiniksa can aggressively fund its pipeline without diluting shareholders.
🐻 Bear Case
As ARCALYST sales scale, so does the profit-sharing burden. Collaboration expenses hit $70M in Q4 (34.6% of revenue), artificially capping operating leverage and net margins.
While Kiniksa dominates with an injectable, upcoming data from competitors developing oral inflammasome inhibitors could challenge the long-term franchise moat if they prove similarly efficacious.
⚖️ Verdict: 🟢🟢
Strongly Bullish. The financial inflection point is firmly in the rearview mirror. Kiniksa is executing a textbook commercial launch, printing cash, and guiding for nearly $1B in FY26 sales.
Key Themes
Deepening Market Penetration
The adoption curve is Accelerating. Kiniksa successfully expanded its active prescriber base to over 4,150 physicians by the end of Q4 (up from 3,825 in Q3). Market penetration in the core multiple-recurrence population expanded from 15% in Q2 to 18% by year-end, validating management's targeted commercial strategy.
Duration of Therapy Validates Chronic Positioning
The average total duration of ARCALYST therapy is now approaching 3 years, Stable and in line with the median duration of the disease itself. This exceptionally high patient retention proves the drug's efficacy and effectively converts new patient starts into multi-year recurring revenue annuities.
Macro Tailwinds: IRA and Gross-to-Net Improvements
The Inflation Reduction Act (IRA) drove a favorable macro shift. Gross-to-net (GTN) improved to 8.4% for FY25, down from 9.8% in FY24. Changes to Medicare Part D out-of-pocket limits reduced the company's co-pay assistance burden, driving patients from free-drug programs to paid commercial therapy and directly boosting the bottom line.
Technological Innovation: Securing the Future with KPL-387
To defend against future competition and address patient fatigue with weekly injections, Kiniksa is advancing KPL-387. This next-generation fully human IgG2 monoclonal antibody targets human IL-1R1 and allows for convenient, once-monthly subcutaneous self-injection in a liquid formulation. Phase 2 dose-focusing data is expected in 2H 2026.
Profit-Share Suppresses Operating Margins
Despite the rosy top-line narrative, the profit-sharing agreement with Regeneron remains a structural ceiling on profitability. Collaboration expenses scale directly with success. In 25Q4, collaboration expenses accounted for $70.0M—meaning nearly 35% of product revenue is immediately siphoned off, limiting true operating leverage.
Growth Rate Normalization
While absolutely massive in dollar terms, the YoY growth rate is Decelerating. FY25 saw 62% YoY revenue growth. The midpoint of FY26 guidance ($910M) implies roughly 34% YoY growth. As the denominator grows and the easy 'early adopter' pool is saturated, maintaining explosive percentage growth will become mathematically harder.
Emerging Inflammasome Competitors
Competitors are developing oral inflammasome inhibitors targeting recurrent pericarditis. While Kiniksa argues that dual IL-1 alpha and beta blockade provides superior, foundational efficacy, any positive clinical data from an oral competitor could pressure ARCALYST's market dominance simply due to the convenience factor.
Other KPIs
Accelerating significantly alongside revenue, up 79% YoY from $128.3 million in FY24. This line item represents Regeneron's share of ARCALYST profitability and will continue to be the largest single expense for the company.
The balance sheet is pristine. The company added $170.4 million in cash over the course of 2025 and carries zero debt. This fortress balance sheet fully de-risks the clinical development of KPL-387 and KPL-1161 without the need for dilutive equity raises.
Decelerating from $111.6 million in FY24. However, investors should expect this to reverse and re-accelerate in FY26 as the pivotal Phase 2/3 trials for KPL-387 fully scale and KPL-1161 enters Phase 1.
Guidance
Decelerating in percentage terms but massive in absolute dollars. The $910M midpoint implies a 34% YoY growth rate (compared to 62% in FY25), adding roughly $232M in new revenue. This reflects continued strong market penetration and duration of therapy.
Stable. Management expects the current operating plan to continue generating positive cash flow, fully self-funding ongoing commercialization and an expanding clinical pipeline.
Key Questions
Gross-to-Net Evolution
With the IRA changes fully annualized in 2026, do you expect the 8.4% gross-to-net ratio seen in FY25 to be the new floor, or are there additional payer mix shifts that could drive it lower?
KPL-387 Transition Dynamics
Regarding the KPL-387 transition study, what are the early signals regarding patient willingness to switch from weekly ARCALYST to monthly KPL-387, and are you seeing any breakthrough flares during the transition protocol?
Capital Allocation
With $414 million in cash, zero debt, and continued positive cash flow expected, how are you evaluating external business development opportunities versus internal pipeline funding or eventual capital returns?
First-Recurrence Penetration
You have previously noted that ~20% of prescriptions come from first-recurrence patients. How fast is this specific cohort growing relative to the core multiple-recurrence population?